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CXCR4 Antagonist AMD3100 Accelerates Impaired
Wound Healing in Diabetic Mice
Yukihide Nishimura1,2,3, Masaaki Ii1,4, Gangjian Qin1, Hiromichi Hamada5, Jun Asai2, Hideya Takenaka2,
Haruki Sekiguchi1, Marie-Ange Renault1, Kentaro Jujo1, Norito Katoh2, Saburo Kishimoto2, Aiko Ito1,
Christine Kamide1, John Kenny1, Meredith Millay1, Sol Misener1, Tina Thorne1 and Douglas W. Losordo1
The antagonism of CXC-chemokine receptor 4 (CXCR4) with AMD3100 improves cardiac performance after
myocardial infarction by augmenting the recruitment of endothelial progenitor cells (EPCs) from the bone
marrow to the regenerating vasculature. We investigated whether AMD3100 may accelerate diabetes-impaired
wound healing through a similar mechanism. Skin wounds were made on the backs of leptin receptor-deficient
mice and treated with AMD3100 or saline. Fourteen days after treatment, wound closure was significantly more
complete in AMD3100-treated mice (AMD3100: 87.0±2.6%, saline: 33.1±1.8%; Po0.0001) and was accompanied
by greater collagen fiber formation, capillary density, smooth muscle–containing vessel density, and monocyte/
macrophage infiltration. On day 7 after treatment, AMD3100 was associated with higher circulating EPC
and macrophage counts, and with significantly upregulated mRNA levels of stromal cell–derived factor 1 and
platelet-derived growth factor B in the wound bed. AMD3100 also promoted macrophage proliferation and
phagocytosis and the migration and proliferation of diabetic mouse primary dermal fibroblasts and 3T3
fibroblasts, which express very little CXCR4. In conclusion, a single topical application of AMD3100 promoted
wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and
enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and
vasculogenesis. Not all of the AMD3100-mediated effects evolved through CXCR4 antagonism.
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INTRODUCTION
Diabetes affects approximately 170 million people world-
wide, including 20.8 million in the US, and these numbers
are projected to double by 2030 (Brem and Tomic-Canic,
2007). In patients with diabetes, impaired angiogenesis and
diminished granulation tissue formation often couple with
other factors, such as decreases in cell and growth factor
response, to reduce peripheral blood flow, which can retard
wound healing and lead to the development of non-healing
foot ulcers (Jeffcoate and Harding, 2003; Falanga, 2005;
Brem and Tomic-Canic, 2007). Non-healing ulcers affect
15% of people with diabetes and are a leading cause of
amputation (Palumbo and Melton, 1995; Jeffcoate and
Harding, 2003; Falanga, 2005; Brem and Tomic-Canic,
2007).
Inflammation is a key component of the wound healing
response and mediates many of the effects induced by
chemokines (Ochoa et al., 2007) such as stromal cell–derived
factor 1 (SDF-1), which binds to CXC chemokine receptor 4
(CXCR4) and regulates both inflammation and cell migration
(Rey et al., 2007). Thus, interactions between SDF-1 and
CXCR4 contribute to cutaneous wound healing (Avniel et al.,
2006), but the mechanisms involved remain incompletely
characterized. Recent experiments conducted in our labora-
tory indicate that administration of the CXCR4 antagonist
AMD3100 promotes neovascularization after myocardial
infarction by mobilizing endothelial progenitor cells (EPCs)
from the bone marrow and by enhancing EPC recruitment to
the sites of ischemia (Jujo et al., 2010). Here, we investigated
whether AMD3100 promotes cutaneous wound healing
through a similar mechanism.
RESULTS
Topical AMD3100 accelerates wound healing in diabetic mice
Full-thickness excisional skin wounds were created on the
backs of db/db mice, treated with AMD3100 or saline, and
examined 0, 7, and 14 days later (Figure 1a). On day 14, the
extent of wound closure was significantly greater (Po0.0001)
& 2012 The Society for Investigative Dermatology www.jidonline.org 711
ORIGINAL ARTICLE
Received 28 April 2011; revised 15 August 2011; accepted 18 September
2011; published online 3 November 2011
1Feinberg Cardiovascular Research Institute, Northwestern University
Feinberg School of Medicine, Chicago, Illinois, USA; 2Department of
Dermatology, Graduate School of Medical Science, Kyoto Prefectural
University of Medicine, Kyoto, Japan; 3Department of Dermatology and
Psychiatry, Nishiyama Hospital, Kyoto, Japan; 4Department of Pharmacology,
Osaka Medical College, Osaka, Japan and 5Department of Pediatrics, Tokyo
Women’s Medical University, Yachiyo Medical Center, Chiba, Japan
Correspondence: Douglas W. Losordo, Feinberg Cardiovascular Research
Institute, Northwestern University, Tarry 14-725, 303 E. Chicago Avenue,
Chicago, Illinois 60611, USA. E-mail: d-losordo@northwestern.edu
Abbreviations: BS-1 lectin, bandeiraea simplicifolia lectin 1; CXCR4, CXC-
chemokine receptor 4; EPC, endothelial progenitor cell; HPF, high-power
field; PDGF, platelet-derived growth factor; PDGFR, PGDF receptor;
SDF-1, stromal cell–derived factor 1
in mice treated with AMD3100 (86.97±2.55%) than in
saline-treated mice (33.07±1.82%; Figure 1b), and histolo-
gical scores were significantly higher for AMD3100-treated
wounds than for wounds treated with saline (Figure 1c–e;
epithelialization: AMD3100, 4.250±0.250, saline, 2.000±
0.408, Po0.005; granulation: AMD3100, 4.750±0.479,
saline, 2.250±0.479, Po0.01; inflammation: AMD3100,
3.750±0.250, saline, 2.500±0.289; Po0.05; Figure 1c–e);
inflammation scores were also significantly higher for
AMD3100-treated wounds on day 7 (AMD3100, 3.500±
0.289, saline, 1.500±0.289, Po0.005). Thick granula-
tion tissue, extensive re-epithelialization, and persistent
inflammation-related acanthosis were observed on the sur-
face of AMD3100-treated wounds, and functional, erythro-
cyte-containing blood vessels were prevalent in the deeper
dermis, whereas saline-treated wounds exhibited a thin
layer of granulation tissue and fewer functional blood vessels
(Figure 1f).
AMD3100 enhances collagen formation at the wound site
Because collagen formation is a crucial component of wound
healing, sections of wound tissue were stained to identify
collagen in the granulation tissue (Masson’s Trichrome
staining) and to assess collagen fiber formation at the wound
center (picosirius red staining), which is the last region of the
wound to heal. Fourteen days after wounding and treatment,
collagen fibers were observed throughout the granulation
tissue in AMD3100-treated wounds, but were restricted
primarily to the edges of saline-treated wounds (Figure 2a).
The collagen fibers in AMD3100-treated wounds were
heterogeneous and appeared to contain a cellular (perhaps
fibroblast) component, which suggests that the fibers were
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Figure 1. Wound healing in diabetic mice. Full-thickness excisional skin wounds were created on the backs of genetically diabetic (leptin receptor–deficient)
mice, treated with 6mg kg1 AMD3100 in 30 ml saline or saline alone, and then examined 0, 7, and 14 days later. (a) Wounds were digitally photographed,
and (b) the extent of wound closure was expressed as the percentage decline in wound area. (c) Epithelialization, (d) granulation, and (e) inflammation scores
ranging from 1 (little or none) to 5 (extensive or severe) were assigned to sections of hematoxylin and eosin–stained wound tissue harvested 14 days after
treatment. Scores were summarized as the mean±SEM for each treatment group. (f) Representative sections of wound tissue harvested 14 days after
treatment; the boxed regions in the upper panels ( 50 magnification) are displayed at higher magnification (200 magnification) in the lower panels.
Functional blood vessels are identified with arrows. Bar¼ 100 mm.
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newly formed; AMD3100-treated wounds also displayed
evidence of persistent acanthosis. At the wound center,
collagen fibers were significantly more common (Po0.05) in
AMD3100-treated wounds (9.210±1.883% of image area)
than in wounds treated with saline (3.901±0.174% of image
area; Figure 2b).
AMD3100 increases capillary density, the formation of smooth
muscle–containing vessels, and monocyte/macrophage
infiltration
Fourteen days after wounding and treatment, capillary
density was significantly higher (Po0.01) in AMD3100-
treated wounds (3.81±0.54% of image area) than in wounds
treated with saline (1.16±0.18% of image area; Figure 2c
and d), and smooth muscle–containing vessel-like structures
were more common in the dermis of the AMD3100 treatment
group (AMD3100: 52.2±8.0 vessels/high-power field (HPF),
saline: 9.8±1.6 vessels per HPF; Po0.001; Figure 2c and e).
Cells stained positively for the monocyte/macrophage-
specific marker CD68 (Figure 2f) were significantly more
prevalent in wounds treated with AMD3100 than in saline-
treated wounds on day 7 (AMD3100: 164.250±26.544 cells
per HPF, saline: 28.750±5.735 cells per HPF; Po0.01;
Figure 2g), and real-time RT-PCR analyses of CD68 mRNA
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Figure 2. Collagen formation, vascularity, and monocyte/macrophage infiltration at the wound site. Collagen formation, vascularity, and monocyte/
macrophage infiltration were evaluated 14, 14, and 7 days, respectively, after wounds were treated with 6mg kg1 AMD3100 in 30 ml saline or saline alone.
(a, b) Collagen formation was assessed in sections of wound tissue stained with Masson’s trichrome or picrosirius red; picosirius red stain accentuates the
birefringence of collagen fibers when viewed under polarized light. The boxed regions in the Masson’s trichrome–stained panels (left) are displayed with
picrosirius red staining in the right panels. Bar¼ 100mm. (b) Fiber formation at the wound center was quantified as the percentage of the digitized image area
that fluoresced red (mature fibers) or yellow-green (immature fibers). (c) Wound tissue sections were stained with FITC-conjugated bandeiraea simplicifolia
lectin 1 (BS-1 lectin, green) to identify endothelial tissue, and with alkaline phosphatase a-smooth muscle actin (aSMA, red) to identify smooth muscle cells.
aSMA-positive vessels are identified with arrows. Bar¼100 mm. (d) Capillary density was quantified as the percentage of the image area that fluoresced
positively for BS-1 lectin and (e) smooth muscle–containing vessels were quantified as the number of structures in the dermis that stained positively for both
BS-1 lectin and aSMA. (f) Sections of wound tissue were stained for expression of the monocyte/macrophage marker CD68 (red); nuclei were counterstained
with 40,6-diamidino-2-phenylindole (blue); bar¼ 100mm. (g) The boxed regions were evaluated for quantification of monocyte/macrophage infiltration (i.e., the
number of CD68-positive cells). HPF, high-power field.
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expression yielded similar results: treatment with AMD3100
was associated with significantly greater CD68 mRNA
expression on day 7 (AMD3100: 230.163±18.913, saline:
69.912±8.638; Po0.0001) but not on day 14 (Figure 3a).
AMD3100 upregulates SDF-1a and platelet-derived growth
factor (PDGF) B mRNA expression at the wound site
Real-time RT-PCR analyses of the expression of SDF-1a
and platelet-derived growth factor (PDGF)-B, which are
known to enhance progenitor cell homing, indicated that
both factors were expressed at significantly higher levels in
wounds treated with AMD3100 than in saline-treated
wounds on day 7 (SDF-1a: AMD3100, 107.160±24.067;
saline, 28.533±1.639; Po0.01. PDGF-B: AMD3100,
5.427±0.626; saline, 2.840±0.319; Po0.001) but not on
day 14 (Figure 3b and c).
AMD3100 mobilizes cells from the bone marrow to the
peripheral circulation
To determine whether the accelerated healing observed after
AMD3100 treatment was associated with enhanced mobili-
zation of cells from the bone marrow, the number of EPCs
and macrophages in the peripheral blood was assessed 7 days
after wounding and treatment. EPCs were identified by DiI-
labeled acetylated low-density lipoprotein uptake and
Bandeiraea simplicifolia lectin 1 (BS-1 lectin) staining,
whereas macrophages were identified via CD68 expression;
isolectin B4 is a marker for macrophage activation (Maddox
et al., 1982; Warfel et al., 1991; Sorokin and Hoyt, 1992;
Guillemin and Brew, 2004), so cells stained positively for
both isolectin B4 and CD68 expression were considered
activated macrophages (Figure 4a). All three cell types were
significantly more common (Po0.0001) in mice treated with
AMD3100 (EPCs: 48.400±2.948 cells per HPF; macro-
phages: 27.600±0.909 cells per HPF, activated macro-
phages: 12.600±1.462 cells per HPF) than in the saline
treatment group (EPCs: 9.500±1.067 cells per HPF, macro-
phages: 7.000±0.816 cells per HPF, activated macrophages:
2.300±0.667 cells per HPF; Figure 4b).
AMD3100 promotes the migration and proliferation of diabetic
mouse primary dermal fibroblasts and the proliferative and
phagocytosis activity of macrophages
The cellular mechanisms responsible for AMD3100-
enhanced wound healing were investigated by evaluating
the migration and proliferation of db/db mouse primary
dermal fibroblasts in 5 and 25mM D-glucose; measurements
were repeated in 25mM D-mannitol to serve as an
osmotic control for the high glucose condition. Fibroblasts
migrated toward 2 mgml1 AMD3100 under all conditions
(Figure 5a and b). In cells cultured at the high glucose
concentration, 2 mgml1 AMD3100 significantly promoted
fibroblast proliferation (Figure 5c), but a higher AMD3100
concentration (10 mgml1) was required to significantly
stimulate proliferation under low glucose or osmotic
control conditions. AMD3100 also promoted the prolifera-
tion (2 mgml1 AMD3100: 0.307±0.013 OD, 0 mgml1
AMD3100: 0.191±0.007 OD; Po0.0001) and phagocytosis
activity (2 mgml1 AMD3100: 0.487±0.019 OD,
0 mgml1 AMD3100: 0.351±0.019 OD; Po0.01) of macro-
phages, but did not significantly affect EPC proliferation
(Figure 5d).
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Figure 3. mRNA expression at the wound site. The expression of (a) CD68,
(b) stromal cell–derived factor 1 (SDF-1)a, and (c) platelet-derived growth
factor (PDGF)-B in wound tissues was assessed 7 and 14 days after wounds
were treated with 6mg kg1 AMD3100 in 30 ml saline or saline alone;
measurements were recorded via quantitative real-time RT-PCR and
normalized to 18S rRNA expression.
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AMD3100 enhances fibroblast migration and proliferation in
the absence of CXCR4 protein expression
AMD3100 is a CXCR4 antagonist, and CXCR4 is expressed in
murine db/db fibroblasts; however, human fibroblasts do not
express CXCR4 (Avniel et al., 2006). Thus, we investigated
whether CXCR4 is required for the AMD3100-induced
enhancement of fibroblast migration and proliferation by
conducting experiments with NIH 3T3 fibroblasts, which
express nearly undetectable amounts of CXCR4 mRNA
(3T3: 0.001±0.0001, db/db: 0.047±0.005; Po0.0001).
The migratory response of 3T3 fibroblasts was significantly
enhanced by AMD3100 (2 mgml1 AMD3100: 250.267±
18.032 cells per HPF, 0 mgml1 AMD3100: 112.167±
17.559 cells per HPF; Po0.0001; Figure 6a), and
AMD3100 also promoted 3T3 fibroblast proliferation
(2 mgml1 AMD3100: 0.337±0.015 OD, 0 mgml1
AMD3100: 0.256±0.008 OD; Po0.001; Figure 6b). To
characterize the molecular mechanisms responsible for
the AMD3100-induced enhancement of 3T3 fibroblast
activity, we measured the mRNA expression of a panel of
candidate factors. After 12 hours in culture, treatment with
AMD3100 was associated with significant upregulation of
SDF-1a (2 mgml1 AMD3100: 104.594±2.234, 0 mgml1
AMD3100: 70.058±4.105; Po0.0001), PDGF-B (2 mgml1
AMD3100: 0.045±0.001, 0 mgml1 AMD3100: 0.014±
0.003; Po0.0001), and monocyte chemotactic protein-1
(2 mgml1 AMD3100: 12.528±1.819, 0mgml1 AMD3100:
6.645±2.121; Po0.05) mRNA expression (Figure 6c).
DISCUSSION
Therapeutic strategies that block the interaction between
CXCR4 and SDF-1 are promising treatments for a variety of
clinical applications. CXCR4 was first identified as a co-
receptor for cellular entry of the HIV (Bleul et al., 1996), and
more recent evidence indicates that CXCR4 has a role in stem
cell trafficking, vascular growth, and cancer metastasis (Petit
et al., 2002; Staller et al., 2003; Yamaguchi et al., 2003;
Urbich and Dimmeler, 2004; Orimo et al., 2005). AMD3100
was the first CXCR4 antagonist to enter clinical trials, and
although it failed as an anti-HIV drug, phase 3 trials for its use
in stem cell mobilization have recently been completed (Adis
Data Information BV, 2007).
Angiogenesis is a crucial component of wound healing
(Singer and Clark, 1999; Falanga, 2005; Brem and Tomic-
Canic, 2007); however, peripheral blood flow is often
impaired in patients with diabetes, which can retard wound
healing and lead to the development of non-healing ulcers
and subsequent amputation (Palumbo and Melton, 1995;
Jeffcoate and Harding, 2003; Falanga, 2005; Brem and
Tomic-Canic, 2007). Current treatments for non-healing
ulcers often combine off-loading (Boulton et al., 2005) with
the administration of growth factors (e.g., PDGF-BB (Smiell,
1998)) and/or cell-based approaches delivered in an absorb-
able mesh (fibroblasts; Marston et al., 2003) or in type 1
collagen (fibroblasts and keratinocytes; Brem et al., 2000).
Here, we investigated whether the angiogenic effects
associated with AMD3100 administration could improve
cutaneous wound healing in genetically diabetic mice,
which, like patients with diabetes, display impairments in
wound healing, granulation tissue formation, and angiogen-
esis (Greenhalgh et al., 1990; Werner et al., 2007). However,
mouse models of chronic wound repair do not always
replicate the human experience, so our findings must be
interpreted with caution.
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Figure 4. Mobilization of bone marrow–derived cells. The number of endothelial progenitor cells (EPCs) and macrophages in the peripheral blood was
determined 7 days after wounds were treated with 6mg kg1 AMD3100 in 30 ml saline or saline alone. (a) Mononuclear cells were isolated from 500ml of
peripheral blood, and then incubated with DiI-labeled acetylated low-density lipoprotein (Dil-acLDL) (red) and stained with FITC-conjugated bandeiraea
simplicifolia lectin 1 (BS-1 lectin, green), or stained for the expression of CD68 (red) and isolectin B4 (green); nuclei were counterstained with 40,6-diamidino-2-
phenylindole (DAPI) (blue). Bar¼ 100mm. (b) EPC counts were quantified as the number of cells stained positively for both DiI-acLDL and BS-1 lectin, total
macrophage counts were quantified as the number of cells stained positively for CD68, and activated macrophages were quantified as the number of cells
stained positively for both CD68 and isolectin B4. HPF, high-power field.
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Our results indicate that topical application of AMD3100
accelerates wound healing in diabetic mice. Wound closure
was 2.5-fold more complete 14 days after treatment with
AMD3100 than after saline treatment and was accompanied
by significantly higher histological scores, notably thicker
granulation tissue (perhaps associated with acanthosis), and
improved collagen deposition and fiber formation. AMD3100
treatment was also associated with greater macrophage
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accumulation and PDGF-B expression at the wound site.
Because PDGF-B promotes macrophage activation, fibroblast
proliferation, and the recruitment of both cell types (Singer
and Clark, 1999), topical AMD3100 treatment likely en-
hances wound healing by inducing a variety of effects in both
macrophages and fibroblasts. However, not all of these
effects can be attributed to CXCR4 antagonism, because
AMD3100 stimulated the migration and proliferation of 3T3
fibroblasts, which express little, if any, CXCR4.
Capillaries and smooth muscle–containing vessels were
more prevalent in AMD3100-treated wounds than in wounds
treated with saline, suggesting that AMD3100 promotes
neovascularization (i.e., the development of new blood
vessels) and vascular remodeling (i.e., arteriogenesis). Neo-
vascularization occurs via two processes: angiogenesis, the
proliferation and migration of preexisting, fully differentiated
endothelial cells in nearby vessels, and vasculogenesis, the
de novo assembly of new blood vessels (Folkman and Shing,
1992; Isner and Asahara, 1999). Historically, vasculogenesis
was believed to occur only during embryogenesis; however,
the results from more recent experiments indicate that EPCs
in the peripheral blood participate in postnatal vasculogen-
esis by incorporating into new vessels and by expressing a
variety of growth factors in ischemic tissue (Asahara et al.,
1997; Isner and Asahara, 1999; Velazquez, 2007; Jujo et al.,
2010). In the absence of ischemia, interactions between
CXCR4 and SDF-1a sequester EPCs in the bone marrow, but
disruption of the SDF-1a/CXCR4 axis with AMD3100
mobilizes these (and other) cells to the peripheral circulation
(Broxmeyer et al., 2005; Shepherd et al., 2006), as evidenced
by the elevated peripheral blood EPC and macrophage counts
observed in mice treated with topical AMD3100.
In both patients and animal models, diabetes is associated
with low circulating EPC counts (Vasa et al., 2001; Tepper
et al., 2002; Schatteman and Ma, 2006; Capla et al., 2007;
Chen et al., 2007; Gallagher et al., 2007) and a loss of SDF-
1a expression in ischemic tissue, which impairs the recruit-
ment of circulating EPCs to the injury site (Brem and Tomic-
Canic, 2007; Gallagher et al., 2007). Impaired EPC recruit-
ment in genetically diabetic mice (Gallagher et al., 2007),
streptozotocin-induced diabetic mice (Sivan-Loukianova
et al., 2003), and in nude mice (Suh et al., 2005) can be
circumvented by administering human EPCs directly to the
cutaneous wound, and both EPC mobilization and recruit-
ment can be enhanced by topical application of SDF-1a to
the wounds of db/db mice (Gallagher et al., 2007). Here, we
demonstrated that topical AMD3100 increases both periph-
eral blood EPC counts and the expression of SDF-1a at the
wound site, so the improved neovascularization and wound
healing associated with AMD3100 treatment likely evolved,
at least in part, via enhanced EPC recruitment. Topical
application of VEGF (Galiano et al., 2004), sonic hedgehog
(Asai et al., 2006b), or dibutyryl cAMP (Asai et al., 2006a) to
cutaneous wounds has also been shown to increase
neovascularization by increasing EPC mobilization and/or
recruitment.
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Figure 6. Activity and mRNA expression in 3T3 fibroblasts after treatment with AMD3100. (a) The migration of 3T3 fibroblasts toward 2mgml1
AMD3100 was evaluated via a modified Boyden’s chamber assay. (b) 3T3 fibroblasts were treated with or without 2 mgml1 AMD3100 for 48 hours,
and then proliferation was evaluated via the CellTiter 96 nonradioactive cell proliferation assay. (c) 3T3 fibroblasts were treated with or without 2 mgml1
AMD3100 for 6 or 12 hours; then, the mRNA expressions of stromal cell–derived factor 1 (SDF-1)a, platelet-derived growth factor (PDGF)-B, and monocyte
chemotactic protein-1 (MCP-1) were assessed via quantitative real-time RT-PCR and normalized to 18S rRNA expression. HPF, high-power field;
OD, optical density.
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Dermal fibroblasts are among the primary targets of PDGF
during cutaneous wound healing (Singer and Clark, 1999).
The two PDGF receptor (PDGFR) subtypes, PDGFR-a and
PDGFR-b, have distinct roles in development, and PDGFR-b
is an important mediator for the contribution of dermal
fibroblasts to wound healing (Gao et al., 2005). The role of
the PDGF-B/PDGFR-b system in adult tissues has been
difficult to characterize, because homozygous disruption of
either PDGF-B or PDGFR-b in mice results in perinatal death
(Gao et al., 2005); however, blockade of PDGF-BB signaling
delays tumor growth (Bergers et al., 2003) and cutaneous
wound healing (Rajkumar et al., 2006). Collectively, these
observations suggest that AMD3100 accelerates wound
healing primarily by increasing fibroblast activity and
noevascularization, although enhancements in keratinocyte
activity and re-epithelialization cannot be excluded.
In conclusion, the results from our investigation indicate
that a single topical application of AMD3100 promotes
cutaneous wound healing and neovascularization in diabetic
mice, and that these effects are likely induced both directly,
through enhanced fibroblast and macrophage activity, and
indirectly, through the stimulation of cytokine production and
the mobilization of progenitor cells from the bone marrow
into the peripheral circulation. However, our findings must
be interpreted with caution, because the results from mouse
models of chronic wound repair do not always predict patient
response. Future investigations are warranted to determine
the potential clinical utility of this compound for the
treatment of non-healing skin ulcers in patients with diabetes
or microvascular disorders.
MATERIALS AND METHODS
Animals, wound model, and treatment
The Institutional Animal Care and Use Committee of Northwestern
University approved all described studies. Experiments were
performed with 10- to 12-week-old female, genetically diabetic,
C57BLKS/J-mþ /þ Leprdb (db/db) mice and their C57BLKS/6J wild-
type littermates (The Jackson Laboratories, Bar Harbor, ME).
Cutaneous wounds were created as described previously (Green-
halgh et al., 1990; Asai et al., 2006a, b; Maruyama et al., 2007) and
as summarized in the Supplementary Methods online. Immediately
after wounding, 6mg kg1 AMD3100 octahydrochloride (Sigma-
Aldrich, St Louis, MO) in 30 ml saline or saline alone was topically
applied to the wound bed, and then a semipermeable transparent
dressing was placed over the wound, secured to the surrounding skin
and muscle with 6-0 Prolene sutures (Covidien, Mansfield, MA), and
left in place until subsequent evaluations were performed (i.e., for up
to 14 days after wounding); suture use was minimized and did not
interfere with wound contraction. The AMD3100 dose was
determined in preliminary experiments: 2, 6, and 10mg doses were
tested, and the 6-mg dose was the minimum dose required to
achieve the greatest acceleration of wound healing.
Wound closure
Wounds were photographed with a digital camera (Nikon Coolpix
995; Nikon, Melville, NY), and then images were analyzed by
tracing the wound margin with a fine-resolution computer mouse
and calculating the enclosed pixel area with the National Institutes
of Health (NIH, Bethesda, MD) Image software (Greenhalgh et al.,
1990; Asai et al., 2006a, b; Maruyama et al., 2007). Measurements
were recorded in duplicate, and the percentage of wound closure
was calculated by using the following equation:
Wound closure ð%Þ
¼ Wound area on day 0Wound area on the indicated day
Wound area on day 0
100%
Histological scores
Wound tissue was harvested, fixed in 100% methanol, processed by
standard methods, and cut into 5 mm sections; then, the sections
were paraffin-embedded, stained with hematoxylin and eosin, and
viewed with an Olympus VANOX AHBT3 (Olympus America,
Center Valley, PA). Epithelialization, granulation, and inflammation
were rated from 1 (little or none) to 5 (extensive or severe) by
investigators who were blinded to treatment as described previously
(Greenhalgh et al., 1990; Asai et al., 2006a, b; Maruyama et al.,
2007) with modifications.
Collagen formation
Collagen formation was evaluated as described previously (Asai
et al., 2006a, b) in 5-mm, paraffin-embedded sections of wound
tissue that were stained with Masson’s trichrome. To evaluate
collagen fiber formation at the wound center, sections were stained
with picosirius red and viewed under polarized light to accentuate
the birefringence of collagen fibers (Junqueira et al., 1979). Fiber
formation was quantified as the percentage of the digitized image
that fluoresced red (mature fibers) or yellow-green (immature fibers).
Wound vascularity
Vasculature in the healing wound was evaluated as described
previously (Asai et al., 2006a, b). Wounds were harvested, sectioned,
and then stained with FITC-conjugated BS-1 lectin and with mouse
monoclonal alkaline phosphatase anti-a-smooth muscle actin
(1:100; Sigma-Aldrich). Nuclei were counterstained with 40,6-
diamidino-2-phenylindole. The sections were viewed with a Carl
Zeiss Axio Observer.D1 (Carl Zeiss MicroImaging, Thornwood, NY;
 50 magnification) and digitally photographed. Capillary density
was quantified as the percentage of the image area that fluoresced
positively for FITC-BS-1 lectin, and smooth muscle–containing
vessels were identified by positive staining for both FITC-BS-1 lectin
and a-smooth muscle actin. Assessments were performed in three
sections, with four HPFs evaluated per section.
Infiltration of monocytes/macrophages
Paraffin-embedded, 5-mm sections of wound tissue were sequentially
stained with rat monoclonal anti-mouse CD68 primary antibodies
(AbD Serotec, Raleigh, NC) and Alexa Fluor 555 goat anti-rat IgG
secondary antibodies (Invitrogen Corporation, Carlsbad, CA).
Secondary staining with normal rat IgG was performed as a negative
control, and nuclei were counterstained with 40,6-diamidino-2-
phenylindole. Sections were viewed with a Carl Zeiss Axio
Observer.D1 and Image J software (NIH; to enable adjustment of
the threshold of fluorescence intensity); cells located at the wound
center and stained positively for CD68 expression were counted in
three sections, with four HPFs evaluated per section.
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Mobilization of bone marrow–derived cells
Circulating EPC levels were evaluated as described previously
(Iwakura et al., 2003). Mononuclear cells were isolated from 500 ml
of peripheral blood via gradient centrifugation with Histopaque-
1083 (Sigma-Aldrich); then, cells were seeded on four-well chamber
slides, coated with rat vitronectin, and cultured in 5% fetal bovine
serum/EBM-2 medium supplemented with growth factors (Single-
Quot Kit; Clonetics, San Diego, CA). After 4 days in culture, cells
were incubated with DiI-labeled acetylated low-density lipoprotein
(Biomedical Technologies, Stoughton, MA) for 1 hour and stained
with FITC-conjugated BS-1 lectin (Vector Laboratories, Burlingame,
CA), and then the slides were viewed with the Carl Zeiss Axio
Observer.D1 and Image J software (NIH). Double-stained cells were
considered to be EPCs and were counted in three wells, with 10
randomly selected HPFs evaluated per well.
To determine the number of monocytes/macrophages present in
the peripheral circulation, mononuclear cells were isolated from
500ml of peripheral blood via a gradient centrifugation, seeded on
four-well chamber slides, and cultured in RPMI 1640 medium
containing 10% heat-inactivated fetal bovine serum. After 4 days in
culture, cells were sequentially incubated with anti-CD68 antibodies
(AbD Serotec), Alexa Fluor 555 goat anti-rat IgG secondary
antibodies (Invitrogen Corporation), and FITC-conjugated isolectin
B4 (Vector Laboratories), and then the slides were viewed with the
Carl Zeiss Axio Observer.D1 and Image J software (NIH). Cells
stained positively for CD68 expression were considered macro-
phages, and cells stained positively for both CD68 and isolectin B4
were considered activated macrophages; the identified cells were
counted in three wells, with 10 HPFs evaluated per well.
Additional cell populations
Primary isolates of dermal fibroblasts, bone marrow-derived macro-
phages, and 3T3 fibroblasts were obtained and cultured as
summarized in the Supplementary Methods online.
Cell functional assays
Migration was evaluated via a modified Boyden’s chamber assay,
proliferation was evaluated via the CellTiter 96 nonradioactive cell
proliferation assay (Promega Corporation, Madison, WI), and
phagocytosis was evaluated via the CytoSelect 96-well phagocytosis
assay (red blood cell, colorimetric format; Cell Biolabs, San Diego,
CA), as directed by the manufacturer’s instructions. The protocols are
summarized in the Supplementary Methods online.
Quantitative real-time reverse transcriptase polymerase
chain reaction
Quantitative real-time reverse transcriptase PCR analyses were
performed using standardized protocols as summarized in the
Supplementary Methods online and normalized to endogenous
18S rRNA expression. Primer and probe sequences are listed in
Supplementary Table S1 online.
Statistical analyses
All results are presented as mean±SEM. Comparisons between two
groups were evaluated with Student’s t-test, and comparisons among
three or more groups were evaluated via one-way analysis of
variance followed by post-hoc testing with the Tukey’s procedure.
A P-value of less than 0.05 was considered statistically significant.
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